Arndt Justus Georg Schottelius
Director/Board Member chez GUBRA A/S
Fortune : 253 515 $ au 31/03/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| John McCafferty | M | 66 |
Maxion Therapeutics Ltd.
 Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 4 ans |
| Harry Welten | M | 59 | 4 ans | |
| Aneesh Karatt-Vellatt | M | 37 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 4 ans |
| Niels Vrang | M | 56 | 16 ans | |
| Alexander Thomas Martensen-Larsen | M | 48 | 2 ans | |
| Uta Kemmerich-Keil | F | 58 | 3 ans | |
| Henriette Draebye Rosenquist | F | 55 | 2 ans | |
| Jacob Jelsing | M | 50 | 16 ans | |
| Kristian Borbos | M | 46 | 2 ans | |
| Constanze Ulmer-Eilfort | M | 62 | 1 ans | |
| Kristoffer Rigbolt | M | - | 2 ans | |
| Trine Nygaard Hamann | F | - | 4 ans | |
| Alexander Fudukidis | M | - | 4 ans | |
| Lucy Edwardes Jones | F | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 ans |
| Thomas Weaver | M | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | - |
| Tim Funnell | M | - |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 2 ans |
| Sohaib Mir | M | 42 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 ans |
| Annalisa Jenkins | M | 58 | 4 ans | |
| Eva-Lotta Allan | F | 65 |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | 1 ans |
| Mads Buhl Axelsen | M | 66 | 2 ans | |
| Henrik Blou | M | 45 | 8 ans | |
| Helle Kirstein Erichsen | F | - | 7 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Adolf Hoess | M | 62 | 14 ans | |
| Ferdinand Verdonck | M | 81 | 7 ans | |
| Berndt A. E. Modig | M | 65 | 6 ans | |
| Angus Smith | M | 41 | 3 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Danemark | 10 | 38,46% |
| Allemagne | 9 | 34,62% |
| Royaume-Uni | 7 | 26,92% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Arndt Justus Georg Schottelius
- Réseau Personnel
